RAC1 and hyperhomocysteinemia: In hyperhomocysteinemia mice, intraperitoneal administration of a Rac1 activator (UTP) promoted whereas a Rac1 inhibitor (NSC-23766) blocked inflammasome activation, podocyte injury, and glomerulosclerosis (43).